These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody. Esswein SR; Gristick HB; Jurado A; Peace A; Keeffe JR; Lee YE; Voll AV; Saeed M; Nussenzweig MC; Rice CM; Robbiani DF; MacDonald MR; Bjorkman PJ Proc Natl Acad Sci U S A; 2020 May; 117(18):9865-9875. PubMed ID: 32321830 [TBL] [Abstract][Full Text] [Related]
10. The epitope arrangement on flavivirus particles contributes to Mab C10's extraordinary neutralization breadth across Zika and dengue viruses. Sharma A; Zhang X; Dejnirattisai W; Dai X; Gong D; Wongwiwat W; Duquerroy S; Rouvinski A; Vaney MC; Guardado-Calvo P; Haouz A; England P; Sun R; Zhou ZH; Mongkolsapaya J; Screaton GR; Rey FA Cell; 2021 Dec; 184(25):6052-6066.e18. PubMed ID: 34852239 [TBL] [Abstract][Full Text] [Related]
11. T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species. Grifoni A; Voic H; Dhanda SK; Kidd CK; Brien JD; Buus S; Stryhn A; Durbin AP; Whitehead S; Diehl SA; De Silva AD; Balmaseda A; Harris E; Weiskopf D; Sette A J Virol; 2020 May; 94(10):. PubMed ID: 32132233 [TBL] [Abstract][Full Text] [Related]
12. Expression and purification of domain III proteins from Dengue and Zika viruses. Corzo-Gómez J; García-Cordero J; Montes Gómez AE; Bernal-Siria K; Namorado-Tónix K; Gutierrez-Castañeda B; Cedillo-Barrón L Protein Expr Purif; 2019 Oct; 162():38-43. PubMed ID: 31112759 [TBL] [Abstract][Full Text] [Related]
13. Zika Virus Envelope Protein and Antibody Complexes. Dai L; Wang Q; Song H; Gao GF Subcell Biochem; 2018; 88():147-168. PubMed ID: 29900496 [TBL] [Abstract][Full Text] [Related]
14. Landscape of Monoclonal Antibodies Targeting Zika and Dengue: Therapeutic Solutions and Critical Insights for Vaccine Development. Dussupt V; Modjarrad K; Krebs SJ Front Immunol; 2020; 11():621043. PubMed ID: 33664734 [TBL] [Abstract][Full Text] [Related]
15. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity. Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880 [TBL] [Abstract][Full Text] [Related]
16. Rational Engineering and Characterization of an mAb that Neutralizes Zika Virus by Targeting a Mutationally Constrained Quaternary Epitope. Tharakaraman K; Watanabe S; Chan KR; Huan J; Subramanian V; Chionh YH; Raguram A; Quinlan D; McBee M; Ong EZ; Gan ES; Tan HC; Tyagi A; Bhushan S; Lescar J; Vasudevan SG; Ooi EE; Sasisekharan R Cell Host Microbe; 2018 May; 23(5):618-627.e6. PubMed ID: 29746833 [TBL] [Abstract][Full Text] [Related]
17. Zika Virus-Like Particles Bearing a Covalent Dimer of Envelope Protein Protect Mice from Lethal Challenge. De Lorenzo G; Tandavanitj R; Doig J; Setthapramote C; Poggianella M; Sanchez-Velazquez R; Scales HE; Edgar JM; Kohl A; Brewer J; Burrone OR; Patel AH J Virol; 2020 Dec; 95(1):. PubMed ID: 33028720 [TBL] [Abstract][Full Text] [Related]
18. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. Dussupt V; Sankhala RS; Gromowski GD; Donofrio G; De La Barrera RA; Larocca RA; Zaky W; Mendez-Rivera L; Choe M; Davidson E; McCracken MK; Brien JD; Abbink P; Bai H; Bryan AL; Bias CH; Berry IM; Botero N; Cook T; Doria-Rose NA; Escuer AGI; Frimpong JA; Geretz A; Hernandez M; Hollidge BS; Jian N; Kabra K; Leggat DJ; Liu J; Pinto AK; Rutvisuttinunt W; Setliff I; Tran U; Townsley S; Doranz BJ; Rolland M; McDermott AB; Georgiev IS; Thomas R; Robb ML; Eckels KH; Barranco E; Koren M; Smith DR; Jarman RG; George SL; Stephenson KE; Barouch DH; Modjarrad K; Michael NL; Joyce MG; Krebs SJ Nat Med; 2020 Feb; 26(2):228-235. PubMed ID: 32015557 [TBL] [Abstract][Full Text] [Related]
19. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design. Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440 [TBL] [Abstract][Full Text] [Related]
20. Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development. Elong Ngono A; Shresta S Front Immunol; 2019; 10():1316. PubMed ID: 31244855 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]